Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 15/20 | 0.92 |
| ▸ | PIM1 | P11309 | 2/20 | 0.92 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.73 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2212280 | 1.00 | PIM2 (0.92) | PIM2PIM1CSNK2A2CSNK2A1KDM4E | |
| SCHEMBL2214127 | 0.96 | PIM2 (1.00) | PIM2PIM1CSNK2A2CSNK2A1KDM4E | |
| SCHEMBL2214123 | 0.96 | PIM2 (1.00) | PIM2PIM1CSNK2A2CSNK2A1KDM4E | |
| SCHEMBL12512853 | 0.88 | PIM2 (0.80) | PIM2PIM1CSNK2A2CSNK2A1CNR1 | |
| SCHEMBL12513074 | 0.88 | PIM2 (0.73) | PIM2PIM1CSNK2A2CSNK2A1CNR1 | |
| SCHEMBL2211724 | 0.88 | PIM2 (1.00) | PIM2PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL2213833 | 0.88 | PIM2 (1.00) | PIM2PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL2214502 | 0.86 | PIM2 (0.78) | PIM2PIM1CSNK2A2CSNK2A1KDM4E | |
| SCHEMBL2214506 | 0.86 | PIM2 (0.78) | PIM2PIM1CSNK2A2CSNK2A1KDM4E | |
| SCHEMBL2214184 | 0.84 | PIM2 (1.00) | PIM2PIM1CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061762-B1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2011-07-27 | — | — | EP | claimed |
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | claimed |
| EP-2061762-A2 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2009-05-27 | — | — | EP | claimed |
| WO-2008022164-A2 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | WO | claimed |
| US-8318723-B2 | Pyrazine compounds, their use and methods of preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318723-B2 | Pyrazine compounds, their use and methods of preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318723-B2 | Pyrazine compounds, their use and methods of preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| EP-2061762-B1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2011-07-27 | — | — | EP | disclosed |
| EP-2061762-B1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2061762-A2 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008022164-A2 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | CDK2, PIM1, CCNK | PIM2 16/4885PIM1 2/4885CSNK2A2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.